Study IDs benefit of donor SCT for adults with acute myeloid leukemia

(Dana-Farber Cancer Institute) A stem cell transplant from a compatible donor early in the course of disease is the best approach for the majority of young and middle-aged adult patients with acute myeloid leukemia, according to a Dana-Farber Cancer Institute study. For AML with “intermediate-risk” (the largest group), there has been no consensus on the best treatment. The Dana-Farber analysis suggests that allogeneic transplant in first remission proved to be the most effective strategy for these patients.

source : www.eurekalert.org

Related News:

• European Medicines Agency Makes Recommendations To Minimise Risk Of…
• Breast Enhancement Surgeon on Long Island Nominated a "Best Of"
• $16 Million Grant From State Stem Cell Agency To Speed Research Of…
• Book and Media Reviews: American Psychiatric Publishing Textbook of…
• After Mastectomy: Making a Decision About Breast Reconstruction
• Robotic Surgery Expert Dr. David B. Samadi Discusses The Benefits Of…
• UM Doctor To Lead Clinical Trial For ALS
• Migraine as inspiration
• Impax Pharmaceuticals Reports Positive Results of Phase II Trial of…
• Analysis of TB treatment studies identifies gaps in guidelines

Details :
Submited at Tuesday, June 9th, 2009 at 8:00 pm on Cancer and Oncology by sofia
Comment RSS 2.0 - leave a comment - trackback